Accenture’s bookings dropped last quarter while earnings per share climbed, with shares falling after the release.
The company’s new bookings were US$20.9 billion, falling 3% year-on-year in U.S. dollars. Its diluted earnings per share were up 7% at $2.82.
“Our second quarter results demonstrate that we continue to deliver on our strategy to lead reinvention for our clients and return to strong growth in FY25, with broad-based growth across markets, industries, and the types of work our clients seek from us,” said Accenture CEO Julie Sweet.
"The trust and confidence in our unique strengths and capabilities is reflected in 32 clients with quarterly bookings greater than $100 million and we are very pleased to have another milestone quarter in Gen AI [generative artificial intelligence] with $1.4 billion in new bookings.”
Total revenue was US$16.66 billion, rising 5% year-on-year. Revenues were highest in the Americas, reaching $8.55 billion after a 9% increase, while Asia Pacific revenue was the only geographical region to see a downturn.
Accenture’s Products segment posted the highest revenue at US$5.05 billion, while its Health & Public Service segment saw the largest percentage increase at 8%. All segments reported year-on-year revenue growth last quarter.
The company will consolidate segments including strategy, consulting, and operations into an arm known as “reinvention services” from September as its AI bookings grow, Sweet said on an earnings call.
Its outlook for fiscal 2025’s third quarter projects revenue of US$16.9-17.5 billion, in line with FactSet estimates of $17.06 billion. Accenture’s full-year guidance now expects diluted earnings per share of $12.55-12.79, up from its previous forecast of $12.43-12.79.
Accenture’s share price has sunk by around 18.2% across 2025, and continues to drop after its earnings release. Shares opened at $279.37 on Friday, down from a previous close of $306.38, before ending the trading day at $285.48.
The company’s market capitalisation is US$178.7 billion.
Related content
